| Description | PPI-1019 is an APP (β-amyloid A4) inhibitor for the treatment of neurological disorders and the study of Alzheimer's disease (AD). |
| In vitro | MTT数据显示，使用SHY5Y细胞，在10 μM Aβ-(1–42)聚集24小时后，PPI-1019的IC50为10 μM。N-甲基化肽PPI-1019在与硫黄素T测定相似的浓度下（IC50=1.6 μM），显示出降低的细胞毒性。[1] |
| Target activity | β-Amyloid (1–42):1.6 μM |
| Synonyms | PPI1019, Apan |
| molecular weight | 650.85 |
| Molecular formula | C36H54N6O5 |
| CAS | 290828-45-4 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 1 mg/mL, Sonication is recommended. |
| References | 1. Amijee H, et al. Inhibitors of protein aggregation and toxicity. Biochem Soc Trans. 2009;37(Pt 4):692-696. 2. Kokkoni N, et al. N-Methylated peptide inhibitors of beta-amyloid aggregation and toxicity. Optimization of the inhibitor structure. Biochemistry. 2006;45(32):9906-9918. |